PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177
Strategic Partnership Supports Commercialization Beyond Ongoing Phase 3 VISION Trial of 177Lu-PSMA-617 WEST LAFAYETTE, Ind. and GARCHING, Germany, July 09, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical group
View HTML
Toggle Summary Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year
Image depicts PSMA PET scans of eight patients with exceptional responses from investigator-sponsored Phase 2 study WEST LAFAYETTE, Ind., June 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,
View HTML
Toggle Summary Endocyte to Join the Russell 3000® Index
WEST LAFAYETTE, Ind. , June 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that its common stock has been selected for inclusion in the broad-market Russell 3000 ® Index
View HTML
Toggle Summary Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Presentations highlight Endocyte’s alpha and beta-emitting radioligand therapies WEST LAFAYETTE, Ind. , June 22, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that multiple
View HTML
Toggle Summary Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer
Additional data from phase 2 investigator-initiated trial of 177Lu-PSMA-617 presented at American Society of Clinical Oncology (ASCO) WEST LAFAYETTE, Ind. , June 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized
View HTML
Toggle Summary Endocyte to Present at Jefferies Healthcare Conference
WEST LAFAYETTE, Ind. , May 29, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the Jefferies Healthcare Conference on Tuesday,
View HTML
Toggle Summary Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
  – PSA response rates in additional 20 mCRPC patients enrolled at Peter MacCallum Cancer Centre higher than previously reported for first group of 30 patients – – Company to host and webcast investor event featuring physician panel on 177 Lu-PSMA-617 – WEST LAFAYETTE, Ind.
View HTML
Toggle Summary Endocyte Announces The Lancet Oncology Publication of Phase 2 Data From Investigator-Initiated Prostate Cancer Trial of (177)Lu-PSMA-617
-Publication includes analysis of original 30 patients previously presented at 2017 ESMO by Professor Michael Hofman of Peter MacCallum Cancer Centre -                -Relative to previously presented data, publication reflects longer median overall survival, longer median prostate specific antigen
View HTML
Toggle Summary Endocyte Provides First Quarter 2018 Financial Results and Operational Update
-Recently Updated Phase 2 Data on 177 Lu-PSMA-617 Published in The Lancet Oncology Favorable to Preliminary Data Presented at 2017 ESMO Congress -        -Positive End of Phase 2 FDA Meeting Set Stage for Successful Financing in First Quarter-                -Phase 3 VISION Trial on Track for First
View HTML
Toggle Summary Endocyte Announces First Quarter 2018 Earnings Call
WEST LAFAYETTE, Ind. , May 02, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company will host a conference call on Wednesday, May 9th , at 8:30 a.m.
View HTML